Total debt has held near $33M to $46M with a debt-to-equity ratio of 0.12, but the current ratio of 1.13 and equity falling from $676.6M to $126.7M before partially rebounding indicate a thin liquidity and capital cushion.
Agilon Health, Inc. (AGL) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 1.4B | 1.1B | 1.46B | 1.48B | 1.45B | 1.37B | 294.2M | 245.53M |
| Cash & Short-Term Investments | 239.76M | 285.14M | 405.6M | 495.1M | 877.2M | 1.05B | 106.8M | 123.63M |
| Cash Only | 174.4M | 173.71M | 193.86M | 114.33M | 465.3M | 1.05B | 106.8M | 123.63M |
| Short-Term Investments | 65.36M | 111.43M | 211.74M | 380.77M | 411.9M | 0 | 0 | 0 |
| Accounts Receivable | 1.02B | 673.79M | 1.02B | 942.46M | 492.36M | 293.41M | 144.56M | 93.25M |
| Days Sales Outstanding | 55.48 | 41.45 | 61.25 | 79.7 | 75.25 | 70.39 | 43.31 | 42.85 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 142.91M | 137.76M | 35.14M | 42.51M | 81.71M | 18.97M | 33.21M | 24.33M |
| Total Non-Current Assets | 165.73M | 174.59M | 276.21M | 260.79M | 246.19M | 219.06M | 152.16M | 157.27M |
| Property, Plant & Equipment | 28.48M | 25.42M | 36.95M | 40.99M | 31.95M | 20.9M | 16.04M | 18.84M |
| Fixed Asset Turnover | 211.75x | 233.41x | 164.01x | 105.31x | 74.74x | 72.80x | 75.95x | 42.18x |
| Goodwill | 0 | 0 | 24.13M | 24.13M | 2.51M | 41.54M | 41.54M | 41.54M |
| Intangible Assets | 56.85M | 65.72M | 72.77M | 63.77M | 18.45M | 55.4M | 60.47M | 71.15M |
| Long-Term Investments | 260.98M | 59.79M | 61.76M | 44.75M | 17.35M | 6.69M | 8.5M | 0 |
| Other Non-Current Assets | 16.43M | 23.66M | 80.6M | 87.15M | 175.93M | 94.53M | 25.61M | 25.74M |
| Total Assets | 1.57B | 1.27B | 1.73B | 1.74B | 1.7B | 1.59B | 446.36M | 402.79M |
| Asset Turnover | 4.05x | 4.67x | 3.50x | 2.48x | 1.41x | 0.96x | 2.73x | 1.97x |
| Asset Growth % | -57.84% | -26.68% | -0.4% | 2.56% | 7.01% | 255.37% | 10.82% | - |
| Total Current Liabilities | 1.23B | 1.08B | 1.15B | 977.16M | 535.09M | 356.96M | 266.83M | 199.61M |
| Accounts Payable | 325.96M | 1.06B | 1.15B | 968.06M | 478.23M | 348.65M | 260.11M | 188.26M |
| Days Payables Outstanding | 45.57 | 63.04 | 69.29 | 83.2 | 76.66 | 87.42 | 84.45 | 89.72 |
| Short-Term Debt | 15.02M | 19.24M | 2.46M | 9.1M | 5M | 8.31M | 3.04M | 3.04M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 51.87M | 0 | 3.68M | 8.31M |
| Current Ratio | 1.13x | 1.02x | 1.27x | 1.51x | 2.71x | 3.83x | 1.10x | 1.23x |
| Quick Ratio | 1.13x | 1.02x | 1.27x | 1.51x | 2.71x | 3.83x | 1.10x | 1.23x |
| Cash Conversion Cycle | 9.91 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.33M | 68.07M | 111.02M | 102.69M | 121.77M | 137.7M | 464.26M | 435.21M |
| Long-Term Debt | 15.51M | 15.75M | 34.9M | 32.31M | 38.48M | 43.4M | 64.67M | 67.14M |
| Capital Lease Obligations | 11.25M | 1.83M | 6.6M | 10.9M | 9.09M | 7.9M | 5.51M | 7.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 10.01M | 12.82M |
| Other Non-Current Liabilities | 32.92M | 50.49M | 69.52M | 59.48M | 74.19M | 86.39M | 384.07M | 347.51M |
| Total Liabilities | 1.28B | 1.14B | 1.26B | 1.08B | 656.86M | 494.66M | 731.09M | 634.82M |
| Total Debt | 33.42M | 36.81M | 43.96M | 52.31M | 52.57M | 59.61M | 73.21M | 77.92M |
| Net Debt | -140.97M | -136.9M | -149.9M | -62.02M | -412.73M | -995.21M | -33.58M | -45.71M |
| Debt / Equity | 0.12x | 0.29x | 0.09x | 0.08x | 0.05x | 0.05x | - | - |
| Debt / EBITDA | -0.41x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.71x | - | - | - | - | - | - | - |
| Interest Coverage | -34.60x | -59.85x | -39.28x | -28.21x | -19.22x | -61.31x | -6.66x | -11.65x |
| Total Equity | 280.88M | 126.73M | 470.95M | 661.02M | 1.04B | 1.09B | -284.73M | -232.03M |
| Equity Growth % | -189.42% | -73.09% | -28.75% | -36.48% | -4.67% | 483.38% | -22.71% | - |
| Book Value per Share | 15.88 | 7.65 | 28.65 | 40.41 | 63.74 | 73.18 | -18.50 | -15.11 |
| Total Shareholders' Equity | 280.88M | 126.73M | 470.95M | 661.84M | 1.04B | 1.09B | -284.73M | -232.03M |
| Common Stock | 168K | 4.15M | 4.12M | 4.06M | 4.12M | 4M | 2.49M | 2.47M |
| Retained Earnings | -1.88B | -1.98B | -1.59B | -1.33B | -1.06B | -957.68M | -551.19M | -491.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -143K | 916K | -88K | -2.3M | -5.56M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | -818K | -611K | -300K | 0 | 0 |
Quick answers to the most common questions about buying AGL stock.
As of 2025, Agilon Health, Inc. (AGL) had total assets of $1.27B including $1.10B in current assets.
Agilon Health, Inc. (AGL) carries total debt of $36.8M, offset by $285.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Agilon Health, Inc. (AGL) has total shareholders' equity (book value) of $126.7M ($7.65 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Agilon Health, Inc. (AGL) reported a current ratio of 1.02x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative margins and equity erosion
Metrics are mathematically derived from official filings.
Equity Eroding as Cushion Thins
Based on AGL's reported figures, shareholders' equity fell from $676.6M in Q2 2024 to $126.7M in Q4 2025 before partially rebounding to $280.9M in Q3 2026, a pattern that suggests the balance sheet cushion has narrowed materially over the period.
The decline in equity appears driven by sustained operating losses rather than leverage, since accumulated deficit stayed near -$1.9B throughout the window. The Q3 2026 rebound is encouraging but reflects a single quarter, so investors should monitor whether equity stabilizes or whether further losses reverse the recovery.
Current Ratio Near Breakeven Level
According to reported balance sheet figures, AGL's current ratio declined from 1.36 in Q2 2024 to 1.02 in Q4 2025 and recovered only modestly to 1.13 in Q3 2026, leaving a thin margin of current assets over current liabilities.
Cash of $174.4M in Q3 2026 provides some buffer, but the ratio suggests limited headroom to absorb an unexpected rise in medical claims payable or a timing mismatch in payer receivables. Given the negative gross margin reported elsewhere in the data, the company's short-term liquidity cushion may be more sensitive to operating drag than the headline ratio implies.
Low Leverage Masks Operating Risk
As reported in financial statements, AGL's total debt has held near $33M to $46M across the ten quarters, producing a debt-to-equity ratio that moved from 0.07 to 0.29 and currently sits at 0.12.
Modest absolute debt and low leverage ratios suggest that financing risk is not the primary constraint on the balance sheet. The rising D/E in late 2025, however, reflects shrinking equity rather than new borrowing, which is a signal of deteriorating capital base rather than strategic leverage.
Asset-Light Profile with Goodwill Swings
Based on AGL's reported figures, goodwill moved from $24.1M to $65.7M and back to $56.9M across recent quarters, while net PP&E stayed in a narrow $25M to $40M range, indicating an asset base dominated by intangibles and light fixed assets.
The goodwill fluctuation implies acquisition or impairment activity that warrants review in the filings, since the change is large relative to the company's equity base. The low PP&E intensity is consistent with a services-oriented model, though it also means the asset base offers limited tangible value in a downside scenario.
Equity Rebound May Prove Transitory
Based on reported figures, the Q3 2026 equity increase to $280.9M from $227.5M may reflect timing or non-operating items rather than durable improvement, given that retained earnings remain near -$1.9B.
A single-quarter equity increase alongside an unchanged accumulated deficit suggests the gain may stem from capital transactions or other non-operating items rather than retained profitability. Investors should examine the equity roll-forward before treating the rebound as evidence of balance sheet repair.